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Abstract
Background: Particularly since the advent of lenalidomide, lower-risk myelodysplastic syndromes (MDS) patients
with del(5q) have been the focus of many studies; however, the impact of age on disease characteristics and
response to lenalidomide has not been analyzed.
Methods: We assessed the effect of age on clinical characteristics and outcomes in 286 lenalidomide-treated MDS
patients with del(5q) from two multicenter trials.
Results: A total of 33.9, 34.3, and 31.8% patients were aged <65 years, ≥65 to <75 years, and ≥75 years, respectively.
Age <65 years was associated with less favorable International Prognostic Scoring System (IPSS) risk and additional
cytopenias at baseline versus older age groups, significantly lower cytogenetic response rates (p = 0.022 vs. ≥65 to
<75 years; p = 0.047 vs. ≥75 years), and higher rates of acute myeloid leukemia (AML) progression (Gray’s test, p = 0.013).
Lenalidomide was equally well tolerated across age groups, producing consistently high rates of red blood cell
transfusion independence ≥26 weeks.
Conclusions: Baseline disease characteristics and AML progression appear to be more severe in younger lower-risk MDS
patients with del(5q), whereas older age does not seem to compromise the response to lenalidomide.
Trial registration: ClinicalTrials.gov NCT00065156 and NCT00179621
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Background
Myelodysplastic syndromes (MDS) occur predominantly
in patients aged ≥60 years, many of whom have limited
treatment options due to comorbidities, functional im-
pairment, or poor medication tolerance [1, 2]. Studies
reporting the effect of age on baseline characteristics
and treatment outcomes in MDS are limited and
usually involve small patient cohorts [3–5]. This study
aims to assess age-related differences in baseline char-
acteristics and outcomes with lenalidomide in red
blood cell (RBC) transfusion-dependent patients with
del(5q) included in two multicenter studies (MDS-003
and MDS-004; ClinicalTrials.gov NCT00065156 and
NCT00179621) [6, 7].
Methods
The methodology of these studies has been described in
detail [6, 7]. Analyses were carried out on the intention-
to-treat population from the MDS-003 and MDS-004
studies. Patients received lenalidomide at one of three
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starting doses and schedules: 5 mg/day, days 1–28
(MDS-004); 10 mg/day, days 1–21 (MDS-003 and MDS-
004); or 10 mg/day, days 1–28 (MDS-003), all given in
28-day cycles. Response rates and outcomes in
lenalidomide-treated patients were analyzed according
to age (i.e., <65 years, ≥65 to <75 years, and ≥75 years).
In MDS-004, patients in the placebo or lenalidomide
5 mg/day group without an erythroid response by week 16
or those who experienced loss of erythroid response, could
cross over to the lenalidomide 5 or 10 mg/day groups, re-
spectively. Rates of RBC transfusion independence (RBC-
TI) ≥26 weeks and cytogenetic response (International
Working Group 2000 criteria [8]) were compared across
age groups using the Tukey test. Duration and time to
RBC-TI were estimated using the Kaplan–Meier method,
with differences evaluated using the Tukey test. Progres-
sion to acute myeloid leukemia (AML) was defined accord-
ing to French–American–British criteria [9]. Time to AML
progression was adjusted for competing risk of death from
other causes using Gray’s test. Time to AML progression
was assessed after lenalidomide treatment failure (defined
as lack of RBC-TI ≥26 weeks or relapse after achievement
of RBC-TI ≥26 weeks with lenalidomide treatment). Rates
of AML progression were analyzed by time since diagnosis;
between-group comparisons and overall comparisons were
carried out using the Tukey test and log-rank test, respect-
ively. Overall survival (OS) was estimated by the Kaplan–
Meier method and differences evaluated using the log-rank
test. OS was also assessed using a Cox proportional haz-
ards model to adjust for differences in life expectancy. Ad-
verse event (AE) severity was graded using the National
Cancer Institute Common Terminology Criteria for Ad-
verse Events, version 3.0, and the incidence compared
across age groups using Fisher’s exact test. Granulocyte-
colony stimulating factor (G-CSF) use, total lenalidomide
dose received, dose reductions, and treatment discontinu-
ation due to AEs were compared across age groups using
Fisher’s exact test.
Results and discussion
This pooled analysis included all 286 patients from the
MDS-003 and MDS-004 studies who received lenalido-
mide from study start (Additional file 1: Figure S1). Me-
dian patient age was 69 years (range, 36–95); detailed
patient characteristics according to age group are pro-
vided in Table 1. Patients were distributed approximately
equally across the three age groups: 97 (33.9%), 98
(34.3%), and 91 (31.8%) patients were aged <65 years,
≥65 to <75 years, and ≥75 years, respectively. More pa-
tients aged <65 years had less favorable International
Prognostic Scoring System (IPSS) risk and a higher
proportion were Intermediate-1-risk than Low-risk,
compared with patients in the ≥65 to <75 years (p =
0.035) and ≥75 years (p = 0.099) groups. The <65 years
group had the highest proportion (48.5%) of patients
with two or three cytopenias compared with the ≥65 to
<75 years (38.8%) and ≥75 years (37.4%) groups. The
higher IPSS categorization and additional cytopenias
suggest that the disease was relatively more severe in
younger patients. Although the patient population in the
two trials was selected (i.e., patients fulfilled a set of
inclusion criteria), this finding has not been reported
previously to our knowledge.
Patients in the <65 years group received a higher me-
dian number of cycles of lenalidomide than those in the
≥65 to <75 years (17 vs. 14; p = 0.130) and ≥75 years
groups (17 vs. 10; p = 0.002; Table 2). The median total
lenalidomide dose received was significantly higher in
the <65 years group (2540.0 mg [range, 65.0–13,730.0])
than in the ≥65 to <75 years (1507.5 mg [range, 30.0–
10,295.0]; p = 0.045) and ≥75 years groups (1070.0 mg
[range, 50.0–10,980.0]; p = 0.001; Table 2).
Rates of RBC-TI ≥26 weeks did not differ among the
age groups, nor did the median time to onset of re-
sponse and duration of response (Table 3). Cytogenetic
response rates (major +minor responses) were signifi-
cantly higher in the ≥65 to <75 years (65.5%; p = 0.022)
and ≥75 years groups (63.5%; p = 0.047) than in the
<65 years group (45.1%; Table 3). The observation that
younger patients had lower cytogenetic response rates
despite a higher total dose is in contrast to the previ-
ously established relationship between lenalidomide dose
and cytogenetic response [7, 10]. The lower response
rate may have resulted from the relatively more severe
disease characteristics in younger patients. In a previous
analysis of p53 status in MDS-004, TP53 mutation and
high p53 protein expression were identified as significant
factors for reduced cytogenetic response in a subset of
patients with biopsies available [11]. In the current
study, however, no differences in p53 protein overex-
pression were observed across the three age groups
(Table 1), whereas TP53 mutation status could not be
assessed.
Lenalidomide was relatively well tolerated in all three
age groups, with low rates of treatment discontinuation.
More patients discontinued due to AEs in the ≥75 years
group compared with the <65 years group (19.8 vs. 8.2%;
p = 0.033; Table 2). The most common grade 3–4 AEs
were neutropenia and thrombocytopenia (Table 4). The
incidence of grade 3–4 thrombocytopenia was signifi-
cantly lower in patients aged <65 years than in patients
aged ≥65 to <75 years (p = 0.004) and ≥75 years (p =
0.019). However, the incidence of grade 3–4 neutropenia
was significantly lower in patients aged ≥75 years than
in patients aged ≥65 to <75 years (p = 0.041). Dose re-
ductions due to thrombocytopenia were more common
in the ≥75 years group compared with the <65 years
group (p = 0.008; Table 2).
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Table 1 Baseline characteristics of lenalidomide-treated patients by age group
Characteristic <65 years
(n = 97)a
≥65 to <75 years
(n = 98)
≥75 years
(n = 91)
Age, years
Median 59 69 79
Range 36–64 65–74 75–95
Female sex, n (%) 71 (73.2)† 56 (57.1)‡ 72 (79.1)
Time since diagnosis, years
Median 2.4 2.7 2.5
Range 0.2–20.7 0.2–14.7 0.1–29.2
Creatinine clearance, ml/min
Median 117.3 88.6 55.5
Range 49.5–259.0 32.3–162.4 18.2–95.6
ECOG performance status score,§ n (%)
0 17 (17.5) 31 (31.6) 11 (12.1)
1 23 (23.7) 22 (22.4) 30 (33.0)
2 3 (3.1) 3 (3.1) 8 (8.8)
Missingb 54 (55.7) 42 (42.9) 42 (46.2)
IPSS risk, n (%)
Low 25 (30.5)** 36 (43.9) 37 (45.7)
Intermediate-1 53 (64.6) 37 (45.1) 39 (48.1)
Intermediate-2 4 (4.9) 6 (7.3) 5 (6.2)
High 0 3 (3.7) 0
Missing 15 (15.5) 16 (16.3) 10 (11.0)
IPSS-R risk, n (%)
Very low 0 1 (1.3) 1 (1.3)
Low 32 (43.2) 30 (38.5) 41 (54.7)
Intermediate 33 (44.6) 35 (44.9) 22 (29.3)
High 8 (10.8) 8 (10.3) 8 (10.7)
Very high 1 (1.4) 4 (5.1) 3 (4.0)
Missing 23 (23.7) 20 (20.4) 16 (17.5)
Cytogenetic abnormalities, n (%)
Isolated del(5q) 63 (64.9) 76 (77.6) 61 (67.0)
del(5q) plus 1 additional abnormality 22 (22.7) 11 (11.2) 17 (18.7)
del(5q) plus ≥2 additional abnormalities 8 (8.2) 5 (5.1) 11 (12.1)
Other or missing data 4 (4.1) 6 (6.1) 2 (2.2)
Number of cytopenias, n (%)
1 50 (51.5) 60 (61.2) 56 (61.5)
2 or 3 47 (48.5) 38 (38.8) 34 (37.4)
Missing 0 0 1 (1.1)c
RBC transfusion burden, units/8 weeks
Median 6 6 6
Range 1–15 1–25 1–12
Hemoglobin level, g/dl
Median 7.4‡‡ 7.8 7.9
Range 4.3–10.0 4.0–10.4 3.6–11.8
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G-CSF prophylaxis for neutropenia did not differ sig-
nificantly across the age groups (data not shown). The
lower rates of neutropenia in the ≥75 years group may
reflect the reduced total dose of lenalidomide in this age
group rather than variations in G-CSF use. Although
grade 3–4 neutropenia occurred less frequently in patients
aged ≥75 years, infectious episodes were more common
(data not shown), a disparity possibly related to the known
natural deterioration of the immune response in older in-
dividuals [12]. Although thrombocytopenia was one of the
most common AEs with lenalidomide, the incidence of
grade 3–4 bleeding events remained low across all age
groups (data not shown).
The cumulative incidence of AML was significantly
lower in the ≥75 years group than in the ≥65 to <75 years
(p = 0.010) and <65 years age groups (p = 0.006; Fig. 1a).
Similarly, the incidence of AML after treatment failure
was significantly lower in the ≥75 years group than in the
≥65 to <75 years (p = 0.006) and <65 years groups (p =
0.022; Fig. 1b). To assess whether this difference could be
attributed to differences in duration of MDS between age
groups, rates of AML progression were analyzed according
Table 1 Baseline characteristics of lenalidomide-treated patients by age group (Continued)
Platelet count, ×109/l
<150 23 (23.7) 32 (32.7) 29 (31.9)
≥150 74 (76.3) 66 (67.3) 62 (68.1)
ANC, ×109/l
Median 1.9 2.1 2.1
Range 0.2–21.0 0.4–10.3 0.3–20.7
Bone marrow blasts, %
Median 3.0 4.0 2.0
Range 0.0–49.0 0.0–19.0 0.0–17.0
p53 protein overexpression in ≥1% cells, n/N (%) 11/34 (32.4) 8/22 (36.4) 11/29 (37.9)
ANC absolute neutrophil count, ECOG Eastern Cooperative Oncology Group, IPSS International Prognostic Scoring System, IPSS-R IPSS–revised, RBC red blood cell
†p = 0.024 vs. ≥65 to <75 years; ‡p = 0.002 vs. ≥75 years; §p = 0.001 for ≥65 to <75 years vs. ≥75 years; **p = 0.035 vs. ≥65 to <75 years; ‡‡p = 0.006 vs. ≥65 to
<75 years; p = 0.003 vs. ≥75 years despite intermittent/recent RBC transfusions
aOne patient in the <65 years group was later diagnosed with acute myeloid leukemia, which had been present at the start of the study
bThe ECOG performance status score could only be determined for patients with this information entered into the study database
cThe number of cytopenias at baseline could not be determined for one patient due to missing ANC data
Table 2 Lenalidomide treatment, rates of dose reduction, and discontinuation by age group
Lenalidomide <65 years
(n = 97)a
≥65 to <75 years
(n = 98)
≥75 years
(n = 91)
Total dose, mg
Median 2540.0† 1507.5 1070.0
Range 65.0–13,730.0 30.0–10,295.0 50.0–10,980.0
Number of cycles
Median 17.0‡ 14.0 10.0
Range 1.0–63.0 1.0–64.0 1.0–62.0
Dose reductions, n (%)
Neutropenia 33 (34.0) 31 (31.6) 23 (25.3)
Thrombocytopenia 13 (13.4)§ 20 (20.4) 27 (29.7)
Neutropenia and thrombocytopenia 6 (6.2) 8 (8.2) 9 (9.9)
Treatment discontinuation, n (%)
Any AEs 8 (8.2)¶ 17 (17.3) 18 (19.8)
Lack of therapeutic effect 14 (14.4) 12 (12.2) 10 (11.0)
Death 2 (2.1) 4 (4.1) 8 (8.8)
AE adverse event
†p = 0.001 vs. ≥75 years; p = 0.045 vs. ≥65 to <75 years; ‡p = 0.002 vs. ≥75 years; §p = 0.008 vs. ≥75 years; ¶p = 0.033 vs. ≥75 years
aOne patient in the <65 years group was later diagnosed with acute myeloid leukemia, which had been present at the start of the study
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to time since diagnosis. Rates of AML did not differ signifi-
cantly between patients with a median duration of MDS
≤1.5 years, >1.5 to ≤3.8 years, and >3.8 years (p = 0.598;
Additional file 2: Table S1).
These findings are consistent with previous long-term
data reported from the MDS-003 study, where achieve-
ment of cytogenetic response was associated with a
lower risk of AML progression in patients with del(5q)
treated with lenalidomide [13]. Although none of the in-
dividual IPSS variables differed significantly between the
age groups (Table 1), a higher proportion of patients
aged <65 years were classified as Intermediate-1-risk,
which may explain their increased risk of AML progres-
sion. Higher IPSS categorization and presence of two or
three cytopenias at baseline were associated with an in-
creased risk of AML progression in a multivariate model
based on data from the MDS-003 study [13]. In a sepa-
rate analysis of untreated patients with lower-risk MDS,
higher rates of AML progression were also seen in pa-
tients aged ≤65 years, with 2-year rates of 6.7 versus
3.0% in patients aged >65 years [14]. These data suggest
that younger patients may have an increased risk of
AML progression regardless of treatment, which is
likely related to the higher-risk disease features of this
patient group.
Median OS was 4.87 years (95% confidence interval
[CI], 3.58–not estimable), 3.46 years (95% CI, 2.31–4.27),
and 2.40 years (95% CI, 2.04–3.22) in the <65 years, ≥65
to <75 years, and ≥75 years groups, respectively (p =
0.001; Fig. 2). OS was not significantly different between
age groups when adjusted for life expectancy based on
the overall population or when analyzed separately
Table 3 RBC-TI ≥26 weeks and cytogenetic response by age group in patients treated with lenalidomide
Response <65 years
(n = 97)a
≥65 to <75 years
(n = 98)
≥75 years
(n = 91)
RBC-TI ≥26 weeks, n (%) 54 (55.7) 53 (54.1) 41 (45.1)
Median time to RBC-TI ≥26 weeks, weeks (range)b 2.48 (1.49–NE) 2.48 (1.36–NE) 7.80 (2.15–NE)
Median duration of RBC-TI ≥26 weeks, years (range)b 4.60 (2.31–NE) 3.19 (1.74–NE) 2.19 (1.20–NE)
Cytogenetic response, n/N (%)
Major +minor 32/71 (45.1)‡ 38/58 (65.5) 33/52 (63.5)
NE not estimable, RBC-TI red blood cell transfusion independence
‡p = 0.022 vs. ≥65 to <75 years; p = 0.047 vs. ≥75 years
aOne patient in the <65 years group was later diagnosed with acute myeloid leukemia, which had been present at the start of the study
bResponding patients only
Table 4 Grade 3−4 AEs by age group reported in ≥5% of patients
AE, n (%) <65 years
(n = 97)a
≥65 to <75 years
(n = 98)
≥75 years
(n = 91)
Patients with ≥1 AE 91 (93.8) 95 (96.9) 89 (97.8)
Neutropenia 73 (75.3) 75 (76.5)† 57 (62.6)
Thrombocytopenia 37 (38.1)‡ 58 (59.2) 51 (56.0)
Anemia 9 (9.3) 12 (12.2) 14 (15.4)
Leukopenia 9 (9.3) 9 (9.2) 15 (16.5)
Pneumonia 4 (4.1) 10 (10.2) 9 (9.9)
Fatigue 1 (1.0)§ 8 (8.2) 3 (3.3)
Dyspnea 2 (2.1) 4 (4.1) 7 (7.7)
Febrile neutropenia 7 (7.2) 5 (5.1) 3 (3.3)
Deep vein thrombosis 2 (2.1) 7 (7.1) 3 (3.3)
Diarrhea 6 (6.2) 7 (7.1) 5 (5.5)
Hypokalemia 4 (4.1) 1 (1.0) 6 (6.6)
Cardiac failure congestive 0¶ 2 (2.0) 5 (5.5)
Fall 0¶ 1 (1.0) 5 (5.5)
Alanine aminotransferase increased 5 (5.2) 2 (2.0) 2 (2.2)
Rash 4 (4.1) 5 (5.1) 4 (4.4)
AE adverse event
†p = 0.041 vs. ≥75 years; ‡p = 0.004 vs. ≥65 to <75 years; p = 0.019 vs. ≥75 years; §p = 0.035 vs. ≥65 to <75 years; ¶p = 0.025 vs. ≥75 years
aOne patient in the <65 years group was later diagnosed with acute myeloid leukemia, which had been present at the start of the study
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according to sex (data not shown). This finding suggests
that the shorter OS in the ≥75 years and ≥65 to <75 years
patient groups likely reflects a higher death rate due to
causes other than AML progression. Concomitant disor-
ders are indeed common in this aged population; in par-
ticular, infection and the presence of anemia were more
frequent in elderly patients. Whereas younger age may
be a favorable factor for survival with lenalidomide, the
more severe disease characteristics seen in patients aged
<65 years suggest that this group may benefit from treat-
ment options other than lenalidomide, followed by allo-
geneic stem cell transplantation in case of primary or
secondary lenalidomide treatment failure.
Lower creatinine clearance rates with increasing age
(Table 1) result in reduced lenalidomide elimination, ul-
timately increasing exposure to the drug [15, 16]. It is
possible that differences in drug metabolism and activity
at the cellular level may have accounted for some of the
apparent age-related differences observed in efficacy
outcomes.
These results should be interpreted with caution given
certain limitations of our analysis. For example, some
mutations such as the TP53 gene mutation and possibly
mutations of other genes (i.e., CSNK1A1, ASXL1, TET2)
are associated with a poor prognosis in patients with
lower-risk MDS with del(5q) [2, 17]. Mutation data were
not collected in the MDS-003 and MDS-004 studies,
and therefore, it could not be determined if certain mu-
tations were more frequent in the <65 years age group.
Of note, however, p53 protein overexpression, a vali-
dated surrogate marker of TP53 gene mutation, was not
influenced by age in the present study.
Conclusions
In summary, age <65 years was associated with poorer
disease characteristics at baseline, lower cytogenetic re-
sponse rates, and higher rates of AML progression than
in the older age groups. These findings suggest that re-
sistance to lenalidomide, or relapse after an initial re-
sponse, may require prompt consideration of allogeneic
stem cell transplantation in younger adult patients with
lower-risk del(5q) MDS. On the contrary, lenalidomide
was equally well tolerated across all age groups, produ-
cing consistently high rates of RBC-TI ≥26 weeks, and
older age did not appear to compromise response to
lenalidomide treatment.
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